Phenotypes and genotypes for CYP2D6 and CYP2C19 in a black Tanzanian population

British Journal of Clinical Pharmacology

Volumn 48, Issue 3, 1999, Pages 395-401

  Bathum, Lise ^a   Skjelbo, Erik ^b   Mutabingwa, Theonest K ^c   Madsen, Hanne ^a   Hørder, Mogens ^a   Brøsen, Kim ^b  

^a ODENSE UNIVERSITY HOSPITAL   (Denmark)

^b UNIVERSITY OF SOUTHERN DENMARK   (Denmark)

^c NATIONAL INSTITUTE FOR MEDICAL RESEARCH   (Tanzania)

Author keywords

Black population; CYP2C19; CYP2D6; Genotype

Indexed keywords

CYCLOGUANIL; CYTOCHROME P450; CYTOCHROME P450 2C19; DEBRISOQUINE 4 HYDROXYLASE; LIPID; MEPHENYTOIN; PROGUANIL; SPARTEINE; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CAUCASIAN; CONTROLLED STUDY; DRUG METABOLISM; FEMALE; GENE DUPLICATION; GENE FREQUENCY; GENOTYPE; HUMAN; HUMAN EXPERIMENT; LIPID METABOLISM; MALE; NORMAL HUMAN; PHENOTYPE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROTEIN EXPRESSION; RACE DIFFERENCE; TANZANIA;

ADULT; AFRICAN CONTINENTAL ANCESTRY GROUP; ALLELES; ARYL HYDROCARBON HYDROXYLASES; CHLOROGUANIDE; CYTOCHROME P-450 CYP2D6; CYTOCHROME P-450 ENZYME SYSTEM; FEMALE; GENETICS, POPULATION; GENOTYPE; HUMANS; MALE; MEPHENYTOIN; MIXED FUNCTION OXYGENASES; PHENOTYPE; SPARTEINE; TANZANIA; TRIAZINES; VARIATION (GENETICS);

EID: 0032868321     PISSN: 03065251     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2125.1999.00019.x     Document Type: Article

References (38)

1. Brøsen K, Rasmussen BB. Selective Serotonin Re-uptake Inhibitors: advances in Basic Research and Clinical Practice, 2nd edn, John Wiley & Sons Ltd, 1996: 87-108.
2. Daly AK, Brockmöller J, Broly F, et al. Nomenclature for human CYP2D6 alleles. Pharmacogenetics 1996; 6: 193-201.
3. Brøsen K, Nielsen PN, Brusgaard K, et al. CYP2D6 genotype determination in the Danish population. Eur J Clin Pharmacol 1994; 47: 221-225.
4. Johansson I, Lundqvist E, Bertilsson L, et al. Inherited amplification of an active gene in the cytochrome P450 CYP2D locus as a cause of ultrarapid metabolism of debrisoquine. Pro Natl Acad Sci 1993; 90: 11825-11829.
5. Drøhse A, Bathum L, Brøsen K, Gram LF. Mephenytoin and sparteine oxidation: genetic polymorphisms in Denmark. Br J Clin Pharmacol 1989; 27: 620-625.
6. Dahl M, Johansson I, Bertilsson L, et al. Ultrarapid hydroxylation of debrisoquine in a Swedish population. Analysis of the molecular genetic basis. J Pharmacol Exp Ther 1995; 274: 516-520.
7. Bathum L, Johansson I, Ingelman-Sundberg M, et al. Ultrarapid metabolism of sparteine: frequency of alleles with duplicated CYP2D6 genes in a Danish population as determined by RFLP and long PCR. Pharmacogenetics 1998; 8: 119-123.
8. Agúndez JAG, Ledesma MC, Ladero JM, Benítez J. Prevalence of CYP2D6 gene duplication and its repercussion on the oxidative phenotype in a white population. Clin Pharmacol Ther 1995; 57: 265-269.
9. Nakamura K, Goto F, Ray WA, McAllister CB, et al. Interethnic differences in genetic polymorphism of debrisoquin and mephenytoin hydroxylation between Japanese and Caucasian populations. Clin Pharmacol Ther 1985; 38: 402-408.
10. Mbanefo C, Bababunmi EA, Mahgoub A. A study of the debrisoquine hydroxylation polymorphism in a Nigerian population. Xenobiotica 1980; 10: 811-818.
11. Lennard MS, Iyun AO, Jackson PR, et al. Evidence for a dissociation in the control of sparteine, debrisoquine and metoprolol metabolism in Nigerians. Pharmacogenetics 1992; 2: 89-92.
12. Woolhouse NM, Eichelbaum M, Oatcs NS. Dissociation of coregulatory control of debrisoquine/penformin and sparteine oxidation in Ghanians. Clin Pharmacol Ther 1985, 37: 512-521.
13. Bertilsson L, Lou YQ, Du YL. Pronounced differences between native Chinese and Swedish populations in the polymorphic hydroxylations of debrisoquine and S-mephenytoin. Clin Pharmacol Ther 1992; 51: 388-397.
14. Kalow W. Interethnic variation of drug metabolism. Trends Pharmacol Sci 1991; 12: 102-107.
15. Johansson I, Oscarson M, Yue Q, et al. Genetic analysis of the Chinese Cytochrome P4502D locus: characterization of variant CYP2D6 genes present in subjects with diminished capacity for debrisoquine hydroxylation. Mol Pharmacol 1994; 46: 452-459.
16. Alvan G, Bechtel P, Iselius L, Gundert-Remy U. Hydroxylation polymorphisms of debrisoquine and mephenytoin in European populations. Eur J Clin Pharmacol 1990; 39: 533-537.
17. Jurima M, Inaba T, Kadar D, Kalow W. Genetic polymorphism of mephenytoin, p. (4′) -hydroxylation: difference between Orientals and Caucasians. Br J Clin Pharmacol 1985; 19: 483-487.
18. de Morais SMF, Wilkinson GR, Blaisdell J, et al. The major genetic defect responsible for the polymorphism of S-Mephenytoin metabolism in humans. J Biol Chemistry 1994; 269: 15419-15422.
19. de Morais SMF, Wilkinson GR, Blaisdell J, et al. Identification of a new genetic defect responsible for the polymorphism of (S)-Mephenytoin metabolism in Japanese. Mol Pharmacol 1994; 46: 594-598.
20. Masimirembwa C, Bertilsson L, Johansson I, et al. Phenotyping and genotyping of S-mephenytoin hydroxylase (cyrochrome P450 2C19) in a Shona population of Zimbabwe. Clin Pharmacol Ther 1995: 57: 656-661.
21. Brøsen K, de Morais SMF, Meyer UA, Goldstein JA. A multifamily study on the relationship between CYP2C19 genotype and S-mephenytoin oxidation phenotype. Pharmacogenetics 1995; 5: 312-317.
22. Skjelbo E, Mutabingwa TK, Bygbjerg I, et al. Chloroguanide metabolism in relation to the efficacy in malaria prophylaxis and the S mephenytoin oxidation in Tanzanians. Clin Pharmacol Ther 1996: 59: 304-311.
23. Vinks A, Inaba T, Otton SV, Kalow W. Sparteine metabolism in Canadian Caucasians. Clin Pharmacol Ther 1982; 31: 23-29.
24. Sanz EJ, Villén T, Alm C, Bertilsson L. S-mephenytoin hydroxylation phenotypes in a Swedish population determined after coadministration with debrisoquine. Clin Pharmacol Ther 1989; 45: 495-499.
25. Heim M, Meyer UA. Genotyping of poor metabolizers of debrisoqume by allele-specific PCR amplification. Lancet 1990; 336: 529-532.
26. Løvlic R, Daly AK, Molven A, et al. Ultrarapid metabolizers of debrisoquine: characterization and PCR-based detection of allels with duplication of the CYP2D6 gene. FEBS 1996; 392: 30-34.
27. Bathum L, Hansen TS, Hørder M, Brøsen M. A dual label oligonucleotide ligation assay for detection of the CYP2C19*1, CYP2C19*2 and CYP2C19*3 alleles involving time resolved fluorometry. Ther Drug Monit 1998; 20: 1-6.
28. Madsen H, Kramer Nielsen K, Brøsen K. Imipramine metabolism in relation to the sparteine and mephenytoin oxidation polymorphisms - a population study. Br J Clin Pharmacol 1995; 39: 433-439.
29. Broly F, Gaedig A, Heim M, et at. Debrisoquine/Sparteine hydroxylation genotype and phenotype: analysis of common mutations and alleles of CYP2D6 in a European population. DNA Cell Biology 1991; 10: 545-558.
30. Masimirembwa CM, Johansson I, Hasler JA, Ingelman-Sundberg M. Genetic polymorphism of cytochrome P450 CYP2D6 in Zimbabwean population. Pharmacogenetics 1993; 3: 275-280.
31. Masimirembwa C, Persson I, Bertilsson L, et al. A novel mutant variant of the CYP2D6 gene (CYP2D6*17) common in a black African population: association with diminished debrisoquine hydroxylase activity. Br J Clin Pharmacol 1996; 42: 713-719.
32. Aklillu E, Persson I, Bertilsson L, et al. Frequent distribution of ultrarapid metabolizers of debrisoquine in an Ethiopian population carrying duplicated and multiduplicated functional CYP2D6 alleles. J Pharmacol Exp Ther 1996; 278: 441-446.
33. Eichelbaum M, Gross AS. The genetic polymorphism of debrisoquine/sparteine metabolism-clinical aspects. Pharmac Ther 1990; 46: 377-394.
34. Rolling MW, Cherrie J, Schell MJ, et al. Lower prevalence of the debrisoquine oxidative poor metaboliser phenotype in American blacks versus white subjects. Clin Pharmacol Ther 1991; 50: 308-313.
35. Persson I, Aklillu E, Rodrigues F, et al. S mephenytoin hydroxylation phenotype and CYP2C19 genotype among Ethiopians. Pharmacogenetics 1996; 6: 521-526.
36. Zang Y, Blouin RA, McNamara PJ, et al. Limitation to the use of the urinary S-/R-mephenytoin ratio in pharmacogenctic studies. Br J Clin Pharmacol 1993; 31: 350-352.
37. Chang M, Dahl M, Tybring G, et al. Use of Omeprazole as a probe drag for CYP2C19 phenotype in Swedish Caucasians - comparison with s-mephenytoin hydroxylation phenotype and CYP2C19 genotype. Pharmacogenetics 1995; 5: 358-363.
38. Johansson I, Lundqvist E, Dahl M, Ingelman-Sundberg M. PCR-based genotyping for duplicated and deleted CYP2D6 genes. Pharmacogenetics 1996; 6: 351-355.